KR-402

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameKR-402

Drug Alias NameKR-402

ClassificationCell and gene therapy > Gene therapy > mRNACell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsAutoimmune DiseasesHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKernal Biologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesKernal Biologics Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A